Escape Bio nabs $73M as race with well-heeled Biogen and Denali heats up
Escape Bio has drifted from the focus that earned it a $63 million Series A in 2017, but that hasn’t hindered the company’s ability to raise cash from bluechip investors.
In what was publicly billed as a crossover round, the neuroscience startup took home $73 million in a raise led by Wellington Capital Management and joined by a slate of new and old investors including the VC arms of Novartis and J&J. That money will help push two experimental drugs deeper into the clinic, including one that pits them in a race with Denali and Biogen, as the company tries to build a precision neuroscience base in South San Francisco.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
